You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Drug Price Trends for CLONIDINE HCL ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for CLONIDINE HCL ER

Average Pharmacy Cost for CLONIDINE HCL ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
CLONIDINE HCL ER 0.1 MG TABLET 68001-0568-06 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 50742-0247-60 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 60687-0462-21 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 00228-4241-06 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 60687-0462-11 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 27241-0108-06 0.32523 EACH 2025-06-18
CLONIDINE HCL ER 0.1 MG TABLET 43547-0435-06 0.32523 EACH 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Clonidine HCL ER

Market Overview

Clonidine HCL ER, a medication primarily used for hypertension, ADHD, and various other therapeutic applications, is experiencing significant market growth. The Clonidine market, which includes Clonidine HCL ER, has expanded from USD 25.65 million in 2023 to USD 26.43 million in 2024, with a projected CAGR of 3.61% until 2030[1].

Therapeutic Applications

Clonidine HCL ER is versatile, with applications in multiple therapeutic areas:

  • Hypertension: It is widely used to manage high blood pressure.
  • ADHD: Particularly effective in pediatric patients, accounting for 81%-92% of prescriptions between 2012 and 2017[4].
  • Pain Management: Used as a non-opioid alternative for pain relief.
  • Menopausal Symptoms: Helps in managing symptoms associated with menopause.
  • Psychiatric Conditions: Used in treating certain psychiatric disorders[1].

Market Drivers

Several factors drive the growth of the Clonidine HCL ER market:

  • Increasing Prevalence of Hypertension and Cardiovascular Diseases: Rising cases of hypertension and cardiovascular diseases increase the demand for Clonidine medications[1].
  • Growing Geriatric Population: The aging population contributes to a higher incidence of chronic conditions that require Clonidine treatment[1].
  • Rising Healthcare Expenditure: Improved access to medical care and increased healthcare spending boost the market growth[1].

Market Restraints

Despite the growth, the market faces several challenges:

  • Alternative Therapies: The availability of alternative treatments for hypertension poses a competitive challenge[1].
  • Side Effects and Adverse Reactions: Potential side effects limit the widespread adoption of Clonidine in clinical settings[1].

Market Opportunities

There are several opportunities for growth and innovation:

  • Advancements in Drug Delivery Systems: Innovations in drug delivery systems, such as extended-release formulations and novel drug-delivery systems, enhance the efficacy and adoption of Clonidine therapies[1].
  • Research and Development: Exploring Clonidine’s potential for treating emerging conditions or co-morbidities can open new therapeutic markets[1].

Price Analysis

The pricing of Clonidine HCL ER varies based on the formulation, dosage, and distribution channel:

Oral Tablets

  • Extended Release 0.1 mg/12 hr: Prices range from $52.70 for 30 tablets, with a per-unit cost of $1.76[5].
  • Generic Versions: The normal cash price for Clonidine HCL ER 0.1 mg extended-release tablets can be around $150.83 for 30 tablets, but discounts can reduce this to as low as $12.01 with coupons[2].

Transdermal Films

  • Extended Release 0.1 mg/24 hr: Prices start from $62.55 for 4 films, with a per-unit cost of $15.64[5].

Cost Savings and Discounts

Patients can significantly reduce their costs using various discount programs:

  • SingleCare Coupons: Can reduce the cost of Clonidine HCL ER to as low as $12.01 for 30 tablets, compared to the normal cash price of $150.83[2].
  • Pharmacy Prices: Prices vary across pharmacies, but discounts and coupons can make the medication more affordable. For example, CVS Pharmacy, Walmart, and Walgreens offer different prices with discounts[2].

Distribution and End-User Segments

The market is segmented by end-users, including:

  • Hospitals: A significant portion of Clonidine sales goes to hospital settings.
  • Clinics: Clinics also constitute a major segment, especially for outpatient treatments.
  • Home Care Settings: With the rise in home care, there is an increasing demand for Clonidine in these settings[1].

Geographic Market

The Clonidine market is global, with opportunities in emerging markets due to improved healthcare infrastructure and increased awareness. The Americas, particularly the U.S., are significant markets, with a substantial portion of sales occurring in retail settings[1].

Competitive Landscape

The Clonidine market is moderately competitive, with opportunities for differentiation through innovation, value-addition, and patient-centric solutions. Companies like AJANTA PHARMA LIMITED are key players, offering generic versions of Clonidine HCL ER, which are significantly cheaper than brand-name versions like Kapvay[2].

Future Projections

Given the current trends, the Clonidine HCL ER market is expected to continue growing:

  • CAGR of 3.61%: The market is projected to grow at this rate until 2030, driven by increasing demand and advancements in drug delivery systems[1].
  • Innovative Research: Focus on developing new delivery methods and exploring Clonidine’s potential for treating emerging conditions will be crucial for sustaining market growth[1].

Key Takeaways

  • Versatile Therapeutic Applications: Clonidine HCL ER is used in multiple therapeutic areas, including hypertension, ADHD, and pain management.
  • Market Growth Drivers: Increasing prevalence of hypertension, growing geriatric population, and rising healthcare expenditure drive market growth.
  • Price Variability: Prices vary based on formulation, dosage, and distribution channel, with significant cost savings available through discounts and coupons.
  • Competitive Landscape: The market is moderately competitive, with opportunities for differentiation through innovation.
  • Future Projections: The market is expected to grow at a CAGR of 3.61% until 2030, driven by increasing demand and innovative research.

FAQs

Q: What are the primary therapeutic applications of Clonidine HCL ER? A: Clonidine HCL ER is primarily used for hypertension, ADHD, pain management, menopausal symptoms, and certain psychiatric conditions.

Q: What drives the growth of the Clonidine HCL ER market? A: The growth is driven by the increasing prevalence of hypertension and cardiovascular diseases, a growing geriatric population, and rising healthcare expenditure.

Q: How can patients reduce the cost of Clonidine HCL ER? A: Patients can use discount programs like SingleCare coupons to significantly reduce the cost of Clonidine HCL ER.

Q: What is the competitive landscape of the Clonidine HCL ER market? A: The market is moderately competitive, with opportunities for differentiation through innovation, value-addition, and patient-centric solutions.

Q: What are the future projections for the Clonidine HCL ER market? A: The market is expected to grow at a CAGR of 3.61% until 2030, driven by increasing demand and advancements in drug delivery systems.

Cited Sources

  1. Research and Markets: Clonidine Market Size, Competitors & Forecast to 2030.
  2. SingleCare: Clonidine Hcl Er Coupons & Prices.
  3. DrugPatentWatch: Drug prices and trends for CLONIDINE.
  4. FDA: Kapvay® (clonidine extended-release) tablets.
  5. Drugs.com: Clonidine Prices, Coupons, Copay Cards & Patient Assistance.
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.